Vanguard Global Advisers
VRCA icon

Vanguard Global Advisers’s Verrica Pharmaceuticals VRCA Stock Holding History

Vanguard Global Advisers’s Portfolio VRCA Stock Details VRCA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.28K Hold
862
– – ﹤0.01% 3547
2026
Q1 		$4.56K Buy
+862
New +$5.52K ﹤0.01% 3565

Other funds holding VRCA

CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Mariner
Mariner Overland Park, Kansas $95.2B AUM 32.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Vanguard Global Advisers's VRCA Position: Q2 2026 in Review

Vanguard Global Advisers held its Verrica Pharmaceuticals (VRCA) position steady in Q2 2026 at 862 shares worth $5.28K. The position accounts for ﹤0.01% of the portfolio, ranked #3547.

Vanguard Global Advisers first reported a position in VRCA in Q1 2026 and has held it in 2 quarters since. 41 funds tracked by Wall St. Rank hold VRCA as of Q2 2026.

  • Vanguard Global Advisers held 862 shares of Verrica Pharmaceuticals worth $5.28K as of Q2 2026.
  • Vanguard Global Advisers left its Verrica Pharmaceuticals share count unchanged in Q2 2026.
  • Verrica Pharmaceuticals made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q2 2026, its #3547 holding.
  • Vanguard Global Advisers first reported a position in Verrica Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • 41 funds tracked by Wall St. Rank held Verrica Pharmaceuticals as of Q2 2026.

Based on Vanguard Global Advisers's 13F filing for Q2 2026, filed 13 Aug 2026.